Arcutis legal chief sells 3,674 shares at $25

Arcutis Biotherapeutics’ EVP and Chief Legal Officer sold 3,674 shares under a Rule 10b5-1 trading plan and now holds 112,508 shares directly.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) executive Matsuda Masaru, EVP and Chief Legal Officer, reported selling 3,674 shares of common stock on September 16, 2026 in an open market or private transaction at a weighted average price of about $25.00 per share, with prices ranging from $25.00 to $25.01. Following this sale, he directly holds 112,508 shares of Arcutis common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026, which has a plan end date of September 1, 2027.

Insider Trade Summary 10b5-1

Net Seller: 3,674 shares

Net Sell 1 txn

Insider Matsuda Masaru

Role See Remarks

Sold 3,674 shs ($92K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,674	$25.0009	$92K

Holdings After Transaction: Common Stock — 112,508 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 3,674 shares Weighted average sale price: $25.0009 per share Sale price range: $25.00–$25.01 per share +3 more

6 metrics

Shares sold 3,674 shares Common stock sale on September 16, 2026

Weighted average sale price $25.0009 per share Common stock sold in multiple transactions

Sale price range $25.00–$25.01 per share Range of prices for the reported sale transactions

Shares owned after transaction 112,508 shares Directly held by Matsuda Masaru following the September 16, 2026 sale

Rule 10b5-1 plan adoption date June 5, 2026 Trading plan under which the reported sale was effected

Rule 10b5-1 plan end date September 1, 2027 Plan end date referenced for the reported transaction

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported ... was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARQT report for Matsuda Masaru?

ARQT reported that Matsuda Masaru, EVP and Chief Legal Officer, sold 3,674 shares of Arcutis Biotherapeutics common stock on September 16, 2026 in an open market or private transaction.

How many ARQT shares does Matsuda Masaru hold after this transaction?

After the reported sale, Matsuda Masaru directly holds 112,508 shares of Arcutis Biotherapeutics, Inc. common stock, as stated in the Form 4 filing.

At what price were the ARQT shares sold in this Form 4?

The sale reported for ARQT used a weighted average sale price of $25.0009 per share. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01 per share, inclusive.

Was the ARQT insider sale by Matsuda Masaru under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026, with a plan end date of September 1, 2027.

What role does the reporting person hold at ARQT?

The reporting person, Matsuda Masaru, serves as EVP, Chief Legal Officer of Arcutis Biotherapeutics, Inc., according to the remarks section of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:17 PM Accepted by SEC EDGAR 09/18/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matsuda Masaru

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		3,674	D	$25.0009(2)	112,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's title: EVP, Chief Legal Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Masaru Matsuda	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)